991 related articles for article (PubMed ID: 32589775)
21. Case report study of the first five COVID-19 patients treated with remdesivir in France.
Dubert M; Visseaux B; Isernia V; Bouadma L; Deconinck L; Patrier J; Wicky PH; Le Pluart D; Kramer L; Rioux C; Le Hingrat Q; Houhou-Fidouh N; Yazdanpanah Y; Ghosn J; Lescure FX
Int J Infect Dis; 2020 Sep; 98():290-293. PubMed ID: 32619764
[TBL] [Abstract][Full Text] [Related]
22. Missed Opportunities on Emergency Remdesivir Use.
Sarpatwari A; Kaltenboeck A; Kesselheim AS
JAMA; 2020 Jul; 324(4):331-332. PubMed ID: 32579163
[No Abstract] [Full Text] [Related]
23. Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit.
Sun D
AAPS J; 2020 May; 22(4):77. PubMed ID: 32458279
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19.
Tempestilli M; Caputi P; Avataneo V; Notari S; Forini O; Scorzolini L; Marchioni L; Ascoli Bartoli T; Castilletti C; Lalle E; Capobianchi MR; Nicastri E; D'Avolio A; Ippolito G; Agrati C;
J Antimicrob Chemother; 2020 Oct; 75(10):2977-2980. PubMed ID: 32607555
[TBL] [Abstract][Full Text] [Related]
25. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status.
Antinori S; Cossu MV; Ridolfo AL; Rech R; Bonazzetti C; Pagani G; Gubertini G; Coen M; Magni C; Castelli A; Borghi B; Colombo R; Giorgi R; Angeli E; Mileto D; Milazzo L; Vimercati S; Pellicciotta M; Corbellino M; Torre A; Rusconi S; Oreni L; Gismondo MR; Giacomelli A; Meroni L; Rizzardini G; Galli M
Pharmacol Res; 2020 Aug; 158():104899. PubMed ID: 32407959
[TBL] [Abstract][Full Text] [Related]
26. Off-Target
Xu Y; Barauskas O; Kim C; Babusis D; Murakami E; Kornyeyev D; Lee G; Stepan G; Perron M; Bannister R; Schultz BE; Sakowicz R; Porter D; Cihlar T; Feng JY
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33229429
[TBL] [Abstract][Full Text] [Related]
27. Removal of Remdesivir's Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19.
Lê MP; Le Hingrat Q; Jaquet P; Wicky PH; Bunel V; Massias L; Visseaux B; Messika J; Descamps D; Mal H; Timsit JF; Peytavin G
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32868327
[TBL] [Abstract][Full Text] [Related]
28. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
29. Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions.
Deb S; Reeves AA
J Pharm Pharm Sci; 2021; 24():277-291. PubMed ID: 34107241
[TBL] [Abstract][Full Text] [Related]
30. Breastfeeding and Respiratory Antivirals: Coronavirus and Influenza.
Anderson PO
Breastfeed Med; 2020 Mar; 15(3):128. PubMed ID: 32129667
[No Abstract] [Full Text] [Related]
31. A Review on Remdesivir: A Broad-spectrum Antiviral Molecule for Possible COVID-19 Treatment.
Khazir J; Maqbool T; Mir BA
Mini Rev Med Chem; 2021; 21(17):2530-2543. PubMed ID: 33596800
[TBL] [Abstract][Full Text] [Related]
32. Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities.
Manjaly Thomas ZR; Leuppi-Taegtmeyer A; Jamiolkowski D; Steveling-Klein E; Bellutti-Enders F; Scherer Hofmeier K; Hartmann K
J Allergy Clin Immunol; 2020 Oct; 146(4):786-789. PubMed ID: 32710973
[No Abstract] [Full Text] [Related]
33. A Review of Remdesivir for COVID-19: Data to Date.
Mehta M; Shyh GI
Cardiol Rev; 2020; 28(6):332-334. PubMed ID: 32773440
[TBL] [Abstract][Full Text] [Related]
34. Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease.
Avataneo V; de Nicolò A; Cusato J; Antonucci M; Manca A; Palermiti A; Waitt C; Walimbwa S; Lamorde M; di Perri G; D'Avolio A
J Antimicrob Chemother; 2020 Jul; 75(7):1772-1777. PubMed ID: 32361744
[TBL] [Abstract][Full Text] [Related]
35. COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.
Andreou A; Trantza S; Filippou D; Sipsas N; Tsiodras S
In Vivo; 2020 Jun; 34(3 Suppl):1567-1588. PubMed ID: 32503814
[TBL] [Abstract][Full Text] [Related]
36. BET 1: The role of remdesivir in COVID-19 infection.
Baombe JP
Emerg Med J; 2020 Aug; 37(8):522-523. PubMed ID: 32753375
[TBL] [Abstract][Full Text] [Related]
37. A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19.
Hashemian SM; Farhadi T; Velayati AA
Drug Des Devel Ther; 2020; 14():3215-3222. PubMed ID: 32821086
[TBL] [Abstract][Full Text] [Related]
38. Remdesivir: First Approval.
Lamb YN
Drugs; 2020 Sep; 80(13):1355-1363. PubMed ID: 32870481
[TBL] [Abstract][Full Text] [Related]
39. Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature.
Musa A; Pendi K; Hashemi A; Warbasse E; Kouyoumjian S; Yousif J; Blodget E; Stevens S; Aly B; Baron DA
West J Emerg Med; 2020 May; 21(4):737-741. PubMed ID: 32726230
[TBL] [Abstract][Full Text] [Related]
40. Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19.
Adamsick ML; Gandhi RG; Bidell MR; Elshaboury RH; Bhattacharyya RP; Kim AY; Nigwekar S; Rhee EP; Sise ME
J Am Soc Nephrol; 2020 Jul; 31(7):1384-1386. PubMed ID: 32513665
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
